Delivery Order SPE2DB22D2005-SPE2DB25FJQX9
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,797.51 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $14,794.36 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation, featuring an ultimate completion date of July 31, 2025. The contract was executed on July 30, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,788.01 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen/ml on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a $50,801.12 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of SKYRIZI 150 mg/mL pen/mL, a pharmaceutical product used to treat inflammatory conditions. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by July 24, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,842.74 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML PENFILL, a pharmaceutical product. The contract is a firm fixed price delivery order with an ultimate completion date of August 4, 2025, and carries no set-aside designation, indicating it was awarded through competitive procurement. The place of performance is located in Conshohocken, Pennsylvania, the company's headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $15,904.96 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors. This firm fixed price, non-competitive delivery order was issued on July 29, 2025, with an ultimate completion date of July 30, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. SKYRIZI is a prescription biologic medication used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $31,745.57 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen injectors on July 24, 2025, with completion targeted for July 25, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is being performed at the contractor's facility in Conshohocken, Pennsylvania. SKYRIZI is a prescription biologic medication used to treat autoimmune and inflammatory conditions, reflecting the federal government's...
- The Defense Logistics Agency awarded a $12,962.95 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of SKYRIZI 150 mg/ml pen injections. This is a firm fixed-price contract with an ultimate completion date of July 28, 2025, and was competitively awarded with no set-aside designation. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $44,915.10 to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of SKYRIZI 150 mg/mL pen/mL, a specialty pharmaceutical product. This firm fixed-price delivery order, with an ultimate completion date of August 5, 2025, is a non-set-aside competitive award and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $63,291.20 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen/mL pharmaceutical supplies. This firm fixed price, competitively awarded delivery order was issued on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJQX9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,515.57 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML pen/milliliter on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. SKYRIZI is a biologic medication used to treat moderate to severe plaque psoriasis and other inflammatory conditions. This delivery order represents a routine pharmaceutical supply transaction supporting the Defense Health Agency and broader military healthcare operations. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, maintains a significant portfolio of federal contracts with DLA covering a comprehensive range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The SPE2DX prime vendor vehicle enables flexible procurement of pharmaceutical commodities to support military healthcare programs globally, with DLA planning to establish next-generation Pharmaceutical Prime Vendor Global Program contracts with multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.5k | 8/5/25 |